#Proton email from switzerland trial#
The aim of the trial is to compare the outcomes of established radiotherapy with proton therapy in the treatment of non small cell bronchial carcinoma – the most common form of lung cancer – in the advanced, inoperable stage. PSI is taking part together with the Radio-Oncology Centre of the Cantonal Hospitals of Aarau (KSA) and Baden (KSB) – the only institutes outside the US to do so. "The patient had an advanced stage tumour that could not be surgically removed." The study is led by the US research organisation overseeing oncologic clinical trials, NRG Oncology. "Today we have used proton therapy, as part of an international Phase 3 clinical trial, to treat our first patient with lung cancer, specifically a non small cell bronchial carcinoma," says Damien Weber, Chief Physician and Head of the Center for Proton Therapy (CPT) at PSI. PSI researchers hope this will extend patient survival rates – even without surgery – and reduce secondary effects caused by radiotherapy, such as heart problems and pneumonitis.
![proton email from switzerland proton email from switzerland](https://emailhow.net/images/protonmail-vs-mailfence.jpg)
For patients in Switzerland, the Paul Scherrer Institute PSI now offers a novel alternative: proton beam therapy (PBT). However, not all tumours can be surgically removed, so scientists are currently conducting intensive research into improving non-invasive treatment methods. In advanced tumours, surgery is followed up with chemotherapy and radiotherapy, and sometimes immunotherapy as well. Surgery is the most usual form of treatment. Lung cancer is the deadliest type of cancer in Switzerland and also one of the most common: it affects around 4,500 patients every year.
![proton email from switzerland proton email from switzerland](https://hitrick.files.wordpress.com/2019/02/protonmail.png)
Equal Opportunities, Diversity & Inclusion.Research Divisions & Labs (only english).5232 - The magazine of the Paul Scherrer Institute.